Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Cosmo Daisey who wrote (1841)	4/30/1998 10:53:00 AM
From: Perry	Respond to of 9523

Any one actually read the CS downgrade. It actually may be a positive in soime ways. They clearly state that this stock os FAIRLY valued at this time so logically any weakness tody would mean it is undervalued. The stock may not be a buy according to CSFB but it sure isn't a sell. I think we'll see some upgrades by other brokerages that have large positions in PFE. Good luck. Perry +++++ RESEARCH ALERT - CS First Boston downgrades Pfizer NEW YORK, April 30 (Reuters) - CS First Boston analyst James Kelly said Thursday he had reduced his rating on Pfizer Inc (PFE - news) to hold from buy. -- Kelly told Reuters he believed high expectations for Pfizer's new impotence drug, Viagra, ''are currently reflected in the (Pfizer) share price. I think the valuation is fair; I don't think it's overblown,'' he added, reffering to the fact that company shares have risen about 50 percent in the year largely on hopes for Viagra, the first pill for impotence, which was launched the week of April 10.